Pfizer Launches Phase III Trial For Sutent In Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive preliminary Phase II results on sunitinib/erlotinib combination therapy were presented at major lung cancer meeting this week in South Korea.
You may also be interested in...
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.
Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent
Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.
Sutent Labeling Updated To Reflect First-Line Renal Cell Carcinoma Data
Study showed sunitinib more than doubled progression-free survival over interferon-alfa.